Please ensure Javascript is enabled for purposes of website accessibility

Why Acadia Pharmaceuticals Stock Is Crashing Today

By George Budwell - Mar 9, 2021 at 9:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An unexpected regulatory setback is weighing on the biotech's shares.

What happened

Shares of the mid-cap biopharma Acadia Pharmaceuticals (ACAD 1.66%) fell by as much as 44% in pre-market trading Tuesday morning. The drugmaker's stock is crashing today in response to a regulatory setback for pimavanserin's proposed label expansion as a treatment for dementia-related psychosis.

The Food and Drug Administration reportedly notified the company on March 3 that it had identified deficiencies in the drug's supplemental New Drug Application (sNDA) that preclude discussion of labeling and post-marketing requirements/commitments. Pimavanserin's sNDA review is still scheduled to be concluded by April 3, despite this unexpected development. 

A man with a worried look staring at his laptop.

Image source: Getty Images.

So what

Pimavanserin is currently approved as a treatment for hallucinations and delusions associated with Parkinson's disease psychosis under the brand name Nuplazid. Acadia has been trialing the drug for several years across a variety of broadly similar indications in the hope of expanding its commercial footprint.

Dementia-related psychosis was set to be the first of these additional indications for the drug -- one that would have likely pushed it into blockbuster territory (greater than $1 billion in annual sales) as soon as next year. So with this high-value label expansion now in jeopardy, at least temporarily, it's not surprising to see investors hitting the exits this morning.  

Now what

Acadia noted in its press release that the FDA has yet to reach a final decision on pimavanserin's sNDA. But the company also revealed that the FDA has yet to share the specifics about the application's problematic areas. As such, it's essentially impossible to make a judgment call on whether this is a minor hiccup or a major setback that could take a prolonged period of time to address. Investors in turn may want to exercise caution with this beaten-down biotech stock today.    

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acadia Pharmaceuticals Stock Quote
Acadia Pharmaceuticals
ACAD
$17.11 (1.66%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.